Effect of AQW051 on Cognitive Function in Patients With Chronic Stable

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Schizophrenia Disorders Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-controlled, Cross-over, Single-dose Study to Evaluate the Effects of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia Including a One Week Multiple-dose Extension to Assess the Persistence of Observed Effects and a Multiple-dose Cross Over Study in Non Smokers Only.

NCT number	NCT01163227
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	May 2010
Completion date	September 2011

Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms